ADEPT System Cancer Imager wins Illinois Tech’s $1 million Nayar Prize Competition

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Illinois Institute of Technology announced a cancer imaging research team is the winner of the final round of the university’s Nayar Prize, which includes a $500,000 personal award to team members. Including previous rounds, this brings the total amount won by this and other teams in the first Nayar Prize competition to $1 million.

The team of Kenneth Tichauer, Illinois Tech associate professor of biomedical engineering; and Jovan Brankov, Illinois Tech associate professor of electrical and computer engineering and of biomedical engineering, and director of the Advanced X-ray Imaging Laboratory developed the Agent-Dependent Early Photon Tomography Cancer Imager with the goal of finding tumors in lymph nodes of breast cancer patients at earlier stages.

The ADEPT System Cancer Imager dyes the entire lymph node, as opposed to a small sample. The combination of the special dyeing process and camera improvements provides a sharper picture of the tissue sample at the molecular level.

The result is a system that allows pathologists to find smaller tumors and prescribe a precise and personalized drug treatment for the patient. Team members estimate 40,000 more women will be properly diagnosed annually using the ADEPT imager.

The team is planning a clinical trial of the ADEPT system, in a partnership with Sanford Research in Sioux Falls, South Dakota, and the University of Chicago Department of Pathology.

The ADEPT Cancer Imager team was selected as one of three finalists for the inaugural Nayar Prize when the competition was announced in 2015, earning $100,000 to continue its research. It was selected from that pool as the sole phase II finalist, earning an additional $200,000 for further research. The team members can use the final, personal $500,000 award at their discretion with no restrictions.

Team members include Miles Wernick, Motorola Endowed Chair Professor of Electrical and Computer Engineering, director of the Medical Imaging Research Center and professor of biomedical engineering; Lori Andrews, distinguished professor of law and director of the Institute for Science, Law, and Technology at Chicago-Kent College of Law; and Yongyi Yang, Harris Perlstein Professor of Electrical and Computer Engineering and professor of biomedical engineering.

YOU MAY BE INTERESTED IN

The tremendous promise—and potential peril—of the prostate-specific antigen (PSA) screening test have confounded guideline developers for decades. When introduced, PSA was one of the first and the only credible blood biomarkers for cancer screening. That a simple blood test should be used to screen for the most common cancer in men, one that was lethal for 3% of men and 5% of Black men, seemed like a slam dunk. 
With artificial intelligence becoming an increasingly ubiquitous part of the fabric of modern life, Cancer Grand Challenges has committed $10 million to a project aimed at developing AI “co-scientists”—AI agents that could help cancer researchers analyze data, generate hypotheses, and suggest new experiments.
For decades, cancer treatment has largely followed a familiar model: Identify the disease, determine its stage, and select the therapy most likely to benefit patients with similar characteristics. Even as targeted therapies and immunotherapies have transformed oncology, we have generally developed drugs for populations rather than individuals.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login